Clinical Trials

Study Title:
A Randomized Phase II Study Comparing Single Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi Arm Trial for Women with Recurrent or Persistent Endometrial Cancer

For more information about the trial above please contact the study team: